Application for approval of avapritinib for the treatment of advanced systemic mastocytosis submitted to the US FDA

Avapritinib is a potent, selective inhibitor of D816V mutant KIT, the primary driver of systemic mastocytosis. It is currently approved in the UK for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumours harboring the PDGFRA D842V mutation.

Source:

Biospace Inc.